FHIR © HL7.org  |  Server Home  |  XIG Home  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Realm US, Authority Hl7

16,400 resources

Type: Text:

By Version

 

Start Prev Rows 7000 - 7200 Next

PackageVersionIdentityName/TitleStatusFMMWGDate
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.439T Categoryactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.440N Categoryactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.441M Categoryactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.442TNM Stage Groupactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.449Opioidsactive2024-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.492Pharmacological interventions for depressionactive2024-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.535Ovarian Canceractive2023-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.536Ovarian Canceractive2023-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.537Fallopian Tube Canceractive2022-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.539Fallopian Tube Canceractive2022-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.541Peritoneal Canceractive2022-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.542Peritoneal Canceractive2023-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.547Cancer Stage 1Cactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.555Gender Femaleactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.556Gender Maleactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.557Pathological N Stage N3aactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.558Pathological N Stage N3bactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.560Rolapitant Oralactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.599Obinutuzumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.600Ofatumumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.602Neurokinin 1 Receptor Antagonistactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.604Serotonin Receptor Antagonistactive2025-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.61Cetuximab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.63Panitumumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.81Palonosetron Oralactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.88Lung Canceractive2015-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.89Lung Canceractive2023-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.95M Stage M0active2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.97Pathological M Stage M1active2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.98Pathological M Stage M1aactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.99Pathological M Stage M1bactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1125.7PROMIS Depression Assessmentactive2023-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.11Sleep Apneaactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.13Septic Shock due to C. Diffactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.15Body Temperatureactive2022-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.16Diarrhea Potentially due to CDIactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.17Abdominal Distensionactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.18Vomiting potentially due to CDIactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.19Ileus due to infectionactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.20Clostridium difficile infectionactive2019-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.3Radiation Therapy Indicators from CPTactive2017-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.4Diagnostic Radiology Surrounding Face and Sinusactive2017-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.5Ear Surgery Affecting the Tympanic Membraneactive2017-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.6Allergic Rhinitis Immunotherapyactive2017-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.8Radiology to Head and Sinusactive2017-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.9Immunotherapy For Allergic Rhinitisactive2022-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1136.63Aortic Dissection or Ruptured Aortic Aneurysmactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.1C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.11C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.12C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.13C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.14C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.15C2S Cannabis Use DIsordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.16C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.17C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.18C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.19C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.2C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.20C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.21C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.22C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.23C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.24C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.25C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.26C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.27C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.28C2S Inhalantsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.29C2S Inhalantsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.3C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.30C2S Inhalantsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.32C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.33C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.34C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.35C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.36C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.38C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.39C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.4C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.40C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.42C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.43C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.44C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.45C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.46C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.47C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.48C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.49C2S Sexuality and reproductive health information sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.5C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.51C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.52C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.53C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.54C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.55C2S Substance Use Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.56C2S Substance Use Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.58C2S Sensitive Categoriesactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.59C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.6C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.60C2S HIV/AIDS information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.65Test C2S Alcohol Use Disordersactive2019-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.67Test C2S HIV/AIDS Information Sensitivityactive2019-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.7C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.8C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.9C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.10Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1002Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1012S. Typhi Infection (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1016S. Paratyphi Infection (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1017S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1021Dark Urine (SNOMED)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1022Acute Onset [Qualifier Value] (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1024Acute Viral Hepatitis (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1027Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1029Listeriosis [Listeria species] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1030Meningitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1032Encephalitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1033Encephalitis [Unspecified Cause] (SNOMED)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1035Indeterminate or Equivocal Lab Result Valueactive2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1037Smoking Status [Current Nonsmoker] (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1040Organisms (Tests by Unspecified Method)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1041Organisms (Tests by Culture and Identification)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1044Candida auris Infection (Tests for Candida auris by Culture and Identification Method)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1045Candida auris Infection (Tests for Candida auris Nucleic Acid)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1047Parkinson’s disease (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1048Parkinson’s disease (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1049Parkinsonism [Secondary] (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1050Parkinsonism [Secondary] (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1065Consciousness [Decreased Level] (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1071Drug Use [IV Evidence] (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1072Miosis (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1076Opioid Overdose and Poisoning (Tests for Opioids [Quantitative])active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1083Rash [Pustular Vesicular] (SNOMED)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1084Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1090Syphilis [Congenital] (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1091Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1092Congenital heart disease (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1093Hearing impairment (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1095Microcephaly (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1096Developmental delay (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1099Congenital heart disease (ICD10CM)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1100Hearing impairment (ICD10CM)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1104Developmental delay (ICD10CM)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1106Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.112Tetanus (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1130Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1131Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassayactive2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1138Staphylococcus Aureus (Tests by Culture and Identification Method)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1139VISA/VRSA (Tests for Vancomycin Resistance Gene)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1145Resistant Lab Result Valueactive2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1148Tests for Vancomycin Susceptibility [Ord]active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1149Proteinuria (Tests for Total Protein in 24H Urine)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.115Mumps (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1150Thrombocytopenia (Tests for Platelets [#/volume] in Blood)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1156Staphylococcus aureus (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1169Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.117Mumps (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1180Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative])active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1186Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative])active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1188Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative])active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1196Anthrax (Tests for Bacillus cereus by Culture and Identification Method)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1197Cervical Lymphadenitis (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1207CRE (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1212Enterobacteriaceae species [Carbapenem Resistant] (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1213NU_Enterobacteriaceae [Carbapenemase Producing] (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1214Carbapenemase resistance mechanism (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1215Tests for carbapenemase productionactive2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1216Tests for carbapenemase resistance mechanismactive2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1217Tests for carbapenem susceptibility [Meropenem, imipenem, and doripenem]active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1218Tests for carbapenem susceptibility [Ertapenem]active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1219Tests for Enterobacter spp., E. coli, or Klebsiella spp. by Culture and Identification Methodactive2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1220NU_Tests for Enterobacteriaceae species by Culture and Identification Methodactive2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1224Therapeutic Response to Medication [Improved]active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1225Altered Mental Status (SNOMED)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1230Eschar (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1231Hypotension (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1233Localized Edema (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1234Localized Edema (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1237Tachycardia (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1238Tachycardia (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1239RCKMS Conditions (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.124Poliomyelitis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1240Maternal Condition Puerperium (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1242Non pestis Yersiniosis Infection (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1244Blastomycosis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1246Blastomycosis (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1249Blastomycosis (Tests for Blastomyces species by Culture and Identification Method)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1250Non pestis Yersiniosis Infection (Tests for Yersinia non pestis species Nucleic Acid)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1251Blastomycosis (Tests for Blastomyces species Nucleic Acid)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1252Blastomycosis (Tests for Blastomyces species Antibody)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1253Blastomycosis (Tests for Blastomyces species Antigen)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1265Fatigue (ICD10CM)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1269Tuberculosis [Latent Infection] (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1274Histoplasmosis (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1275Histoplasmosis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1281Histoplasmosis (Tests for Histoplasma capsulatum H band or M band Antibody)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1294Abscess [Liver, Lung, Spleen, Prostate, or Brain] (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1295Seizure [Unspecified Cause] (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1298Abscess [Liver, Lung, Spleen, Prostate, or Brain] (ICD10CM)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1299Seizure [Unspecified Cause] (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.130Influenza (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1304Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species in Extrapulmonary Specimen by Culture and Identification Method)active2025-02